• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

    4/24/26 9:28:23 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRIX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Nurix Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    67080M103

    (CUSIP Number)
    04/20/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    Redmile Group, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,696,314.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,696,314.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,696,314.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile"), including RedCo II Offshore SPV LLC ("RedCo II SPV"), is incorporated by reference herein. Percentage based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q for the quarterly period ended February 28, 2026 filed with the Securities and Exchange Commission on April 8, 2026 (the "Form 10-Q") plus (ii) 3,664,406 shares of Common Stock issuable upon exercise of certain of the Pre-Funded Warrants to purchase Common Stock (the "Warrants") held directly by certain investment vehicles, including RedCo II SPV, managed by Redmile (the "Redmile Funds"), which due to the Beneficial Ownership Limitation (as defined in Item 4) is the maximum number of shares that could be issued to the Redmile Funds upon exercise of the Warrants.


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    Jeremy C. Green
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,696,314.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,696,314.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,696,314.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy C. Green is incorporated by reference herein. Percentage based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 3,664,406 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by the Redmile Funds, including RedCo II SPV, which due to the Beneficial Ownership Limitation (as defined in Item 4) is the maximum number of shares that could be issued to the Redmile Funds upon exercise of the Warrants.


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    RedCo II Offshore SPV LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,967,424.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,967,424.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,967,424.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    FI, OO

    Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by RedCo II SPV is incorporated by reference herein. Percentage based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 2,881,142 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by RedCo II SPV.


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    RedCo II Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN, FI

    Comment for Type of Reporting Person:  Following the internal reorganization among certain Redmile Funds described in Item 4 below, RedCo II Master Fund, L.P. beneficially owned no shares of the Issuer's Common Stock.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Nurix Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1600 Sierra Point Parkway Brisbane, CA 94005
    Item 2. 
    (a)Name of person filing:

    Redmile Group, LLC Jeremy C. Green RedCo II Offshore SPV LLC RedCo II Master Fund, L.P.
    (b)Address or principal business office or, if none, residence:

    Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 RedCo II Offshore SPV LLC c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 RedCo II Master Fund, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939
    (c)Citizenship:

    Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom RedCo II Offshore SPV LLC: Cayman Islands RedCo II Master Fund, L.P.: Cayman Islands
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    67080M103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Redmile Group, LLC - 10,696,314 (1) Jeremy C. Green - 10,696,314 (1) RedCo II Offshore SPV LLC - 5,967,424 (2) RedCo II Master Fund, L.P. - 0
    (b)Percent of class:

    Redmile Group, LLC - 9.9% (3) Jeremy C. Green - 9.9% (3) RedCo II Offshore SPV LLC - 5.6% (4) RedCo II Master Fund, L.P. - 0.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Offshore SPV LLC - 0 RedCo II Master Fund, L.P. - 0

     (ii) Shared power to vote or to direct the vote:

    Redmile Group, LLC - 10,696,314 (1) Jeremy C. Green - 10,696,314 (1) RedCo II Offshore SPV LLC - 5,967,424 (2) RedCo II Master Fund, L.P. - 0

     (iii) Sole power to dispose or to direct the disposition of:

    Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Offshore SPV LLC - 0 RedCo II Master Fund, L.P. - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Redmile Group, LLC - 10,696,314 (1) Jeremy C. Green - 10,696,314 (1) RedCo II Offshore SPV LLC - 5,967,424 (2) RedCo II Master Fund, L.P. - 0 (1) As of April 20, 2026, Redmile Group, LLC's and Jeremy Green's beneficial ownership of Common Stock is comprised of 7,031,908 shares of Common Stock owned by certain investment vehicles, including RedCo II Offshore SPV LLC ("RedCo II SPV"), for which Redmile Group, LLC ("Redmile") is the investment manager/adviser (the "Redmile Funds"). Subject to the Beneficial Ownership Blocker (as defined below), Redmile and Mr. Green may also be deemed to beneficially own 4,708,469 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants to purchase Common Stock (the "Warrants") held by the Redmile Funds, including RedCo II SPV. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrants, and a holder of any Warrants shall not be entitled to exercise the Warrants held by such holder, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of Common Stock would be aggregated with such holder's for the purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and the applicable regulations of the Securities and Exchange Commission, including any "group" of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (the "Beneficial Ownership Blocker"). The "Beneficial Ownership Limitation" is 9.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The 10,696,314 shares of Common Stock reported as beneficially owned by Redmile in this Schedule 13G represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (3) below) and includes 3,664,406 shares of Common Stock issuable under the Beneficial Ownership Blocker. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such shares, if any. (2) On April 20, 2026, in connection with an internal reorganization of RedCo II Master Fund, L.P. ("RedCo II Master"), a private investment vehicle managed by Redmile, Redco II Master contributed all of its securities of the Issuer pro rata and in kind, for no consideration, to its two wholly-owned subsidiaries (collectively, the "SPVs"), including RedCo II SPV. As a result of the internal reorganization, (i) RedCo II Master ceased to have voting or dispositive power over any of the Issuer's securities and, therefore, is no longer a beneficial owner of more than 5% of the Issuer's Common Stock and will be dissolved, and (ii) RedCo II SPV became a beneficial owner of more than 5% of the Common Stock. The 5,967,424 shares of Common Stock reported as beneficially owned by RedCo II SPV includes 3,086,282 shares of Common Stock and 2,881,142 shares of Common Stock issuable upon exercise of the Warrants under the Beneficial Ownership Blocker. Accordingly, this Schedule 13G serves as an exit filing for RedCo II Master and as an initial filing for RedCo II SPV. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green. (3) Percentage for Redmile and Jeremy Green based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 3,664,406 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by the Redmile Funds, including RedCo II SPV, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued to the Redmile Funds upon exercise of the Warrants. (4) Percentage for RedCo II SPV based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 2,881,142 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by RedCo II SPV.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See the response to Item 4.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Redmile Group, LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member
    Date:04/24/2026
     
    Jeremy C. Green
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Jeremy C. Green
    Date:04/24/2026
     
    RedCo II Offshore SPV LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of Redmile Group, LLC, its manager
    Date:04/24/2026
     
    RedCo II Master Fund, L.P.
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of RedCo II (GP), LLC, General Partner of RedCo II Master Fund, L.P.
    Date:04/24/2026
    Get the next $NRIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRIX

    DatePrice TargetRatingAnalyst
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    11/24/2025$30.00Buy
    Truist
    10/21/2025$24.00Outperform
    Mizuho
    3/17/2025$16.00Market Perform
    Leerink Partners
    12/10/2024$35.00Buy
    BTIG Research
    12/6/2024$35.00Outperform
    BMO Capital Markets
    10/24/2024$35.00Buy
    UBS
    10/11/2024$41.00Buy
    Jefferies
    More analyst ratings

    $NRIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

    In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK degradation in blood and skin Phase 1 studies support continued exploration of new tablet formulation in inflammation and immunology indications BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the

    5/14/26 4:05:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics to Participate in Upcoming Investor Conferences

    BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences: RBC Global Healthcare ConferenceWednesday, May 20, 2026, at 1:30 p.m. ET. Jefferies Global Healthcare ConferenceWednesday, June 3, 2026, at 11:05 a.m. ET. The fireside chats will be webcast live and may be viewed via a link in the Investors section

    5/13/26 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

    BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Oral Presentation Details: Title: Updated efficacy and safety data

    5/12/26 4:05:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $NRIX
    SEC Filings

    View All

    $NRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chief Legal Officer Ring Christine exercised 3,422 shares at a strike of $1.86 and sold $135,253 worth of shares (8,148 units at $16.60) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 13,579 units (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    6/2/26 7:14:20 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Silva Paul M

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    5/15/26 5:56:53 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Saltzman Edward C

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    5/15/26 5:55:29 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    5/15/26 4:03:04 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Nurix Therapeutics Inc.

    SCHEDULE 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)

    5/6/26 11:30:07 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

    SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    4/24/26 9:28:23 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Nurix Therapeutics with a new price target

    Truist resumed coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $30.00

    11/24/25 9:17:24 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Nurix Therapeutics with a new price target

    Mizuho initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $24.00

    10/21/25 7:21:21 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Leadership Updates

    Live Leadership Updates

    View All

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

    NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi

    4/8/25 4:00:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

    SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies. "Roy has been a trusted advisor to Nurix since 2023, and I am delighted to welcome him to our board

    3/13/25 4:00:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Financials

    Live finance-specific insights

    View All

    $NRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

    600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced t

    10/22/25 6:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

    Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin

    6/12/25 6:59:59 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

    SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress in Milan, Italy. Details of the webcast and conference call are as follows: Date and time: Thursday, June 12, 8:00 a.m. ET / 2:00 p.m. CEST Access details: The live webcast will be a

    6/6/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:21:48 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:08:39 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care